Chimeric antigen receptor T-cell (CAR-T) therapy and immune checkpoint inhibitors are emerging as promising therapeutic approaches for prostate cancer and rely on targeting increased expression of antigens on prostate cancer cells, such as prostate-specific membrane antigen (PSMA), or modulating the expression of increased immunosuppressive receptors, such as PD-L1, respectively [142,218,219]. Here, FOLH1 is linked to prostate cancer.